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Abstract
Introduction
Phototype has been associated with an increased risk of prostate cancer, and it is yet
unknown if it is related to other hormone-dependent cancers, such as breast cancer or
whether this association could be considered causal.
Methods
We examined the association between the phototype and breast and prostate cancers
using a Mendelian randomization analysis. We studied 1,738 incident cases of breast can-
cer and another 817 cases of prostate cancer. To perform a Mendelian randomization analy-
sis on the phototype—cancer relationship, a genetic pigmentation score was required that
met the following criteria: (1) the genetic pigmentation score was associated with phototype
in controls; (2) the genetic pigmentation score was not associated with confounders in the
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relationship between phototype and cancer, and (3) the genetic pigmentation score was
associated with cancer only through its association with phototype. Once this genetic score
is available, the association between genetic pigmentation score and cancer can be identi-
fied as the association between phototype and cancer.
Results
The association between the genetic pigmentation score and phototype in controls showed
that a higher genetic pigmentation score was associated with fair skin, blond hair, blue eyes
and the presence of freckles. Applying the Mendelian randomization analysis, we verified
that there was no association between the genetic pigmentation score and cancers of the
breast and prostate.
Conclusions
Phototype is not associated with breast or prostate cancer.
Introduction
Breast and prostate cancer (hormone dependent cancers) are leading causes of cancer related
deaths in the Western world. Breast cancer (BC) is the most frequent type of cancer in women
worldwide and a main cause of cancer related deaths in developed countries[1] while prostate
cancer (PCa) is the second most frequent cancer among men worldwide, following lung can-
cer. In addition, the incidence of both cancers is growing in both Western [1] and Eastern
countries [2] due, on the one hand, to increased exposure to environmental risk factors and
the aging of the population and, on the other hand, to the improved diagnostic techniques and
generalization of screening.
Epidemiological research has led to the identification of several BC risk factors associated
with the production of estrogen (age at menarche, parity, age at first full-term pregnancy, age
at menopause),[3,4] and a number of risk factors related to lifestyle (tobacco smoking, alcohol
consumption, being overweight or obesity)[5], although their importance seems to be lower
than the estrogen-related factors. Risk factors can only explain 40% of the risk of BC. Com-
pared to other common cancers, the etiology of PCa remains a mystery. Although inflamma-
tion, diet, physical inactivity, weight, waist circumference and high body mass index (BMI),
play a role as risk factors for PCa[6–12], their link to its etiology remain uncertain and the only
well-established risk factors for PCa are family history, ethnicity and age[13–17]. Some genetic
variants have also been found to be associated with BC and PCa; for instance, variants in
BRCA1 and BRCA2 are strongly associated with BC[18,19], and some genetic scores have
been developed for both types of cancer[20,21].
Pigmentation phenotypes
The growth and survival of BC and PCa is regulated by the gonadal steroid hormones. Two
therapeutic subtypes of estrogen, ERα and ERβ receptors that mediate the action of estrogen
and are factors of nuclear transcription, are considered therapeutic targets for BC and PCa
[22]. Estrogens can increase tyrosinase activity and melanin content in normal skin [23]; it is
noteworthy that ERb is more frequent in both skin and prostate tissue than ERa[23]. More-
over, estrogens can regulate skin pigmentation via G-protein coupled receptors[24].
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As far as we know, there is one study that evaluates the relationship between exposure of
pigmentation phenotypes (eye color, hair color, skin phototype, and the presence of freckles,
and the way in which exposure to the phenotype was measured) and the incidence of BC[25].
We have also identified two studies that directly examined the relationship between pigmenta-
tion phenotypes and the incidence of PCa, another hormone-dependent tumor. On the one
hand, Bonilla et al found that British white men who were more likely to have freckles, a lighter
skin color and were more prone to burning than tanning had a higher risk of developing PCa
than men without such variants[26] However, it is unclear whether these links are coinciden-
tal. In fact, the findings may be due to confounders simultaneously associated with the fair
skin phototype and cancer, such as ultraviolet radiation (UV) exposure, seasons of the year,
level of vitamin D or use of sun cream with high protection. On the other hand, Weinstein
et al. paper found no association between eye color and skin phototype[27], but red-haired
participants in the study were significantly less likely to develop PCa than men with light
brown hair[27].
Moreover, to our knowledge, there are only two prospective studies that investigate the rela-
tionship between phenotype and cancer[25,27]; reverse causality, therefore, may explain some
associations between cancers and sun exposure, as patients could change their habits after
receiving a cancer diagnosis. In this same way, prospective studies do not support the hypothe-
sis that the relationship between personal UV radiations (UVR) lowers the incidence of BC
[25]. An information bias could also have occurred, since most of the studies that observed
associations between phototype and cancer have used self-reported (subjective) data on hair,
skin and eye color and amount of sun exposure sun instead of objectively measured data.
Mendelian randomization
To solve this problem, we have used the Mendelian randomization analysis [28,29], this
method was also used by Bonilla in 2013 [26].This is an epidemiological approach that aims to
avoid confounding, measurement problems and reverse causality through the use of genetic
variants with effect on a modifiable exposure such as the phenotype of skin, eyes, hair and
freckles[30–33]. Mendelian randomization is not influenced by reverse causality because these
genetic variants are established at conception and could be considered randomly assigned at
conception in relation to probable confounding factors. If the phenotype is truly a causal risk
factor in cancer development, it would be expected that genetic variants that modify the phe-
notype will also increase the risk of cancer. Thus, to assess the relationship between pigmenta-
tion traits (eye color, hair color, skin phototype, and the presence of freckles) and the risk of
BC and PCa, in this article, we built a genetic score associated with pigmentation characteris-
tics and analyzed its relationship with BC and PCa in a case-control study conducted in Spain.
Methods
Study design and population
It is a population-based case-control study carried out in 12 Spanish provinces. This study
called Multicase-control (MCC-Spain) evaluates five common types of cancer in Spain (breast,
prostate, colorectal, stomach, and chronic lymphocytic leukemia) and has previously been
detailed in another article [34].
Cases and controls were recruited between September 1st, 2008 and December 31st, 2013.
In this analysis, we included 1,738 incident cases of BC in women and their 1,910 controls, and
817 incident cases of PCa and their 1,006 controls. Subjects were drafted from 23 hospitals and
primary care centers across 12 Spanish provinces. All cases had received pathology-confirmed
diagnosis; they were between 20 and 85 years old and lived in the vicinity of each hospital at
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least 6 months before diagnosis. Controls, people from the same catchment area as the cases,
without BC or PCa history, were chosen at random from the lists of General Practitioners at
primary health centers; they were frequency matched by recruitment province and age (±5
years). Response rates were 72% among cases and 52% among controls. Ethnicity can be a
potential variable of confusion, since skin pigmentation is related to ethnicity (perhaps as a
consequence of melanosome size and the substantial variation in melanin composition[35]),
and ethnicity is related to PCa incidence as well as other variables, all cases and controls
selected were white or caucasian.
This study was approved by each of the ethics committees of the participating institutions
(the Clinical Research Ethics Committee of Asturias, Barcelona, Cantabria, Girona, Granada,
Gipuzkoa, Huelva, Leo´n, Madrid, Murcia, Navarra and Valencia). In addition, all the partici-
pants included in the study were fully informed and signed a consent form and all procedures
performed on humans were carried out in accordance with the ethical standards of the institu-
tional and / or national research committee and taking into account the Declaration of Hel-
sinki of 1964 and its subsequent modifications or comparable ethical standards.
Data collection
Trained, experienced personnel conducted comprehensive interviews to evaluate sociodemo-
graphic information, anthropometric data, smoking habits, alcohol consumption, reproduc-
tive history, and personal and family history of cancer of the participants. BMI was calculated
taking into account self-reported weight and height records noted one year before diagnosis
for cases and one year before the interview for controls. Pigmentation (hair, skin and eye color
or freckles) and phototype (classified applying the Fitzpatrick scheme[36], were also self-
reported. Behavior of the skin in the sun (classified applying the Fitzpatrick scheme) was cate-
gorized into four type of skin (skin type 1: I get tanned easily, I don’t get burn; skin type 2: I
rarely get burned and then I get tanned; skin type 3: I get burned and then I get tanned and
skin type 4: I get burned and almost never I get tanned). Hair color type was categorized into
five graded types of category (black or very dark brown, brown, light brown and blonde). Eye
color was divided into three categories, blue or grey, green or light brown and dark brown.
Genotyping and SNP selection for the genetic risk scores
Blood samples were obtained following the study protocol[37]. The genotyping was carried
out using the Infinium Human Exome BeadChip (Illumina, San Diego, USA) which is made
up of>200,000coding markers plus 5,000 additional custom SNPs chosen from prior
genome-wide association studies (GWAS) or in genes of interest. The principal components
were estimated using the PLINK—cluster command, which implements complete linkage
agglomerative clustering based on pairwise identity-by-state distance.
Genetic variants linked to pigmentation phenotypes in GWAS were identified using GWAS
catalog Genomebrowser [38] after searching for pigmentation phenotypes as “reported trait”
with a p-value threshold of 5×10−8, evident in European ancestry (initial or replication sam-
ple). For this analysis, 18 of these pigmentation susceptibility variants could be included.
Finally, rs12931267 had to be eliminated given that it was in linkage disequilibrium with
rs1805007 SNPs (r2 >0.8). In accordance with Hardy-Weinberg equilibrium (HWE) no SNP
was rejected as no SNP achieved statistical significance (p< 10−4) in the HWE test. The com-
plete list of 17 SNPs obtained from the literature is detailed in S1 Table. In order to build a
genetic pigmentation score (GPS), genotypes of these 17 SNPs were codified as 0, 1 or 2 and
added for obtaining the GPS in such a way that higher scores were associated with light-color
eyes, blonde hair, fairer skin, freckles, and skin getting more easily burned or tanned; finally,
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the SNP codes. Note that, although our GPS is constituted by the SNPs selected from the litera-
ture, the risk allele for each variant originates from a SNP by SNP analysis with our data, hence
it may not match that reported originally. Such a SNP by SNP analysis tests for the association
between each variant and the 5 phototype traits discussed earlier, even if no association
between the SNP and a particular trait has been published. For example, rs1015362 is associ-
ated with hair colour, freckles and tanning in the literature, whereas in our data it shows a sig-
nificant association with eye colour.
Statistical analysis
For performing a Mendelian randomization analysis on phototype–cancer relationship, the
GPS needs to meet with the following criteria: (1) the GPS is associated with phototype in con-
trols; (2) the GPS is independent of confounders; and (3) the GPS is not associated with cancer
conditional on the phototype and confounders of the relationship between phototype and can-
cer[39]. Once such a GPS is available, the association between the GPS and cancer can be iden-
tified as the association between the phototype and cancer.
Then, we tested the first criterium, i.e.: whether the GPS was associated with pigmentation
variables and sun exposure; this was assessed in controls by multinomial logistic regression
[40]. The results are presented as relative risk ratio (RRR) with 95% confidence intervals (CI).
Note that the p-value, along with both the F statistic and R2, refer to the difference between the
model including only the propensity score and the model including the pigmentation pheno-
type and the propensity score.
The second criterium (the GPS is independent from confounders) was tested by studying
the association between prostate or BC risk factors and the GPS in controls. We categorized
the GPS in quartiles and carried out statistical tests with chi-square or anova, according to the
characteristics of the potential confounder.
The third criterium, i.e.: whether the GPS was NOT associated with cancer but via photo-
type was examined with MR-Egger method[39]. In order to do it, linear regression models
were built with SNP–cancer association as Y variable and SNP–phenotype association as X
variable, weighted by the inverse of variance.
The associations between the pigmentation phototype or GPS and BC and PCa were stud-
ied using logistic regression. To avoid bias linked to differences in case and control selection
frequencies, each analysis was performed separately for BC and PCa and adjusted for a pro-
pensity score, which was designed including the recruiting center, the first 3 main principal
components of genetic ancestry taken from genotyping data, age, education level, BMI the
year before the tumor, and tobacco consumption five years before [41]. F statistics obtained as
Chi square / (number of categories in the phenotype– 1) and provided an overall p-value for
each model. Finally, as a sensitivity analysis, we constructed five different genetic pigmentation
scores, one for each pigmentation trait (eye color, hair color, skin phototype, and the presence
of freckles and tanning), from our data (S2 Table) we analyzed their relationship with cancer
in the same way we have described for the GPS.
Results are reported as odds ratios (OR) with 95% confidence intervals (CI). All reported p-
values are two-tailed. All statistical analyses were performed with the software Stata 14/SE
(Stata Co., College Station, TX, US).
Results
Sample description and variables
1,738 BC cases and 1,910 controls (1,138 cases and 1,240 controls with genetic information)
and 1,112 PCa cases and 1,493 controls (817 cases and 1,094 controls with genetic
Pigmentation phototype and prostate and breast cancer—A Mendelian randomization analysis in the MCC-Spain
PLOS ONE | https://doi.org/10.1371/journal.pone.0201750 August 14, 2018 5 / 15
information) were included in the analysis; their main characteristics are reported in S3 Table.
BC cases, compared to their controls, were 2.6 younger in average, the average age (SD) being
56.4 (12.6) years for cases and 59.0 (13.2) years for controls and their age at menopause was
48.8 years in both groups (SD 5.5 for cases and 5.3 for controls). There were no differences in
BMI, tobacco consumption and education level. On the other hand, in the PCa collection, the
average age was 66 years [(66.1 (7.3) for cases and 66.5 (8.6) for controls)]. PCa cases, com-
pared to their controls, were 0.5 younger on average, and they had a lower education level with
higher percentage of cases with primary level education only (39% vs. 32%) or less (23% vs.
19%). PCa cases and controls were similar in BMI and tobacco consumption.
Pigmentation phototype and breast or prostate cancer
Skin, and hair color, and the presence of freckles response to the sun were not associated with
the likelihood of developing BC or PCa (Table 1). However, having light brown or green eyes
was associated with a 25% lower risk of BC (OR 0.75, 95% CI 0.61 to 0.91) and dark brown
eyes a 21% lower risk of PCa (OR 0.79, CI 95%: 0.64 to 0.99), compared to having them dark
brown.
Mendelian randomization, criterium 1: Association of genetic
pigmentation score and phototype in controls
Table 2 shows the association between the reported phototype and the GPS in controls for BC
and PCa. Higher GPS was associated with fairer skin, blonde hair, blue eyes and presence of
freckles. In addition, we could observe that when the GPS is divided into quartiles (Fig 1), the
RRR pattern in any of these characteristics is similar: fixing the quartile of the GPS, RRR
increases with fairer phototype, and fixing the phototype, RRR increases with higher GPS
quartile. We carried out a sensitivity analysis using 5 specific genetic pigmentation scores for
eye color, hair color, skin phototype, the presence of freckles and skin tanning; all five genetic
pigmentation scores were developed using part of the 17 SNPs included in GPS. Each genetic
pigmentation score was associated with its related phenotype as displayed in S4 Table. Thus,
hair-color score explains a 3.7% of the variability in hair color while the eye-color score
explains a 4.6% of the eye color. In the same way, higher hair-color score was associated with
blonde hair (RRR 1.48 (1.35–1.62)) and higher eye-color score was associated with blue / grey
(RRR 1.78 (1.63–1.94)).
Mendelian randomization, criterium 2: The genetic pigmentation score is
not associated with the confounders in the pigmentation–breast or prostate
cancers relationships
S5 Table displays the results for the association between the GPS and risk factors for BC or PC
showing a lack of such a relationship.
Mendelian randomization, criterium 3: The genetic pigmentation score is
not associated with cancer conditional on the phototype and confounders
of the relationship between phototype and cancer
S6 Table shows the results of MR-Egger to test whether GPS is associated with cancer only
through its association with the phototype; (i.e.: no horizontal pleiotropy). In this able, βrepre-
sents an estimation of the phototype effect on cancer and α represents the bias that Mendelian
randomization is introducing when estimating the phototype–cancer relationship (i.e.: the
direct effect of GPS on cancer). Our results indicate that horizontal pleiotropy cannot be ruled
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out in skin color and skin behavior in the sun–PCa relationships, as α estimations differed
from 0; the β estimates suggest that fairer skin and skins which burn or tan easily are associated
with a lower risk of PCa, with odds ratios around 0.89. S1 Fig shows several plots of SNP effect
on cancer vs SNP effect on the different phototype traits.
Applying Mendelian randomization: Association between genetic
pigmentation score and cancer
When we analyzed the association between GPS and cancer (Table 3), we verified that neither
PCa nor BC were associated in the whole population. The same occurred when stratifying by
age (<65 years /65 years), BMI (<25 kg/m2 /25 kg/m2) and menopausal status in women.
As the clinical relevance of PCa with Gleason score< 7 is controversial, we reanalyzed the
Table 1. Relationship between phenotype and prostate and breast cancer.
Prostate cancer Breast cancer
Phenotype Category Cases Controls OR 95% CI p F p R2
(%)
Cases Controls OR 95% CI p F p R2
(%)
Hair color dark hair 919
(83.1)
1067
(83.4)
1 1.00 0.367 0.08 1301
(75.6)
1292
(74.2)
1 0.94 0.390 0.06
Light brown hair 83
(7.5)
99(7.7) 1.29 (0.90–
1.85)
0.158 266
(15.4)
301(17.3) 0.93 (0.73–
1.17)
0.518
blonde hair 104
(9.4)
113(8.8) 1.12 (0.79–
1.57)
0.530 155
(9.0)
149(8.6) 1.11 (0.81–
1.53)
0.518
Skin color Dark skin 263
(23.8)
306(21.1) 1 1.57 0.207 0.12 243
(14.0)
277(14.7) 1 0.34 0.727 0.02
Light brown skin 386
(34.9)
542(37.3) 0.89 (0.72–
1.12)
0.332 626
(36.1)
681(36.2) 0.93 (0.77–
1.13)
0.461
Fair skin 458
(41.4)
604(41.6) 1.13 (0.88–
1.46)
0.341 864
(49.9)
922(49.0) 0.93 (0.70–
1.24)
0.627
Eye color Black/dark brown 623
(56.2)
742(51.1) 1 1.89 0.150 0.15 987
(56.9)
967(51.4) 1 3.33 0.036 0.22
Light brown/
green
325
(29.3)
473(32.6) 0.79 (0.64–
0.99)
0.040 509
(29.3)
622(33.1) 0.75 (0.61–
0.91)
0.005
Blue/grey 161
(14.5)
238(16.4) 0.91 (0.69–
1.21)
0.533 239
(13.8)
292(15.5) 1.09 (0.84–
1.41)
0.531
Freckles No 185
(16.7)
297(20.5) 1 5.44 0.066 0.31 472
(27.2)
578(30.7) 1 3.19 0.074 0.11
Yes 919
(83.0)
1153
(79.5)
1.27 (0.98–
1.64)
0.070 1254
(72.3)
1303
(69.3)
1.09 (0.89–
1.32)
0.410
Behavior of the
skin in the sun
I get tanned
easily, I don’t get
burn
476
(43.0)
607(42.2) 1 1.02 0.385 0.12 618
(35.6)
657(35.0) 1 1.74 0.914 0.02
I rarely get
burned and then I
get tanned
220
(19.9)
289(20.1) 1.28 (0.98–
1.67)
0.070 329
(19.0)
377(20.1) 0.87 (0.67–
1.11)
0.259
I get burned and
then I get tanned
257
(23.2)
344(23.9) 1.02 (0.80–
1.31)
0.847 421
(24.3)
461(24.6) 1.04 (0.83–
1.31)
0.741
I get burned and
almost never I get
tanned
154
(13.9)
198(13.8) 1.04 (0.78–
1.40)
0.774 366
(21.1)
382(20.4) 1.02 (0.80–
1.31)
0.858
Model adjusted for propensity score
F statistics obtained as Chi square / (number of categories in the phenotype– 1). F, p and R2 refer to the comparison between the model with genetic score + propensity
score and the model with only the propensity score
https://doi.org/10.1371/journal.pone.0201750.t001
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GPS–PCa association stratifying cases according to their Gleason score, again obtaining no
association between GPS and PCa (results not shown). Also, when performing logistic regres-
sion analyses on specific genetic pigmentation scores and BC or PCa, the results indicated that
none of these genetic scores was associated with PCa or BC.
Discussion
In our study, the advantages of the method of Mendelian randomization were used to verify
whether there was a causal relationship between phototype (eye color, hair color, skin photo-
type, and the presence of freckles) and the risk of BC and PCa. We found that phototype was
not associated with BC or PCa. Mendelian randomization uses genetic markers as instrumen-
tal variables or proxies for the exposure (phototype). Thus, our genetic marker was a genetic
score combining alleles which have been described previously as associated with phototype
(hair, skin, eyes and freckles); according to our analysis, this genetic score was not associated
with the risk of BC or PCa.
To the best our knowledge, only two studies have directly examined the relationship
between the exposure of pigmentation phenotypes (eye color, hair, skin and the presence of
freckles as the way in which exposure to the phenotype was measured) and the incidence of
PCa [26,27]; however, the epidemiological evidence is still inconsistent. Results found in an
observational study may be due to confounding factors associated with fair skin phototype and
cancer simultaneously. A number of putative confounders have been identified, namely expo-
sure to UV rays, seasons of the year; use of high factor sun cream, level of vitamin D or estro-
gen levels, could be mediators in such a relationship [42,43]. For example, a possible protective
effect of exposure to UV on PCa was hypothesized to be mediated through the increase of vita-
min D level resulting from the synthesis of vitamin D epidermal induced by sunlight[43,44].
On the other hand, some studies have shown an inverse association between vitamin D levels
Table 2. Relationship in controls between the genetic pigmentation score of the phototype (for each unit of increase) and the phototype. Relative Risk Ratio (RRR)
and 95% Cis.
RRR (95% CI) Genetic pigmentation score
Phenotype Category N (%) RRR (95% CI) F p R2(%)
Hair color Dark hair 1779(78.62) 1 (reference) 9.09 <0.001 1.13
Light brown hair 290(12.84) 1.12 (1.06–1.18)
Blonde hair 193(8.54) 1.20 (1.12–1.28)
Skin color Dark skin 365(15.76) 1 (reference) 16.58 <0.001 1.52
Light brown skin 881(38.04) 1.16 (1.09–1.22)
Fair skin 1070(46.2) 1.27 (1.20–1.34)
Eye color Black/dark brown 1176(50.71) 1 (reference) 24.29 <0.001 2.20
Light brown/green 792(34.15) 1.13 (1.08–1.18)
Blue/grey 351(15.14) 1.31 (1.23–1.38)
Freckles No 1723(74.36) 1 (reference) 15.63 <0.001 1.13
Yes 594(25.64) 1.09 (1.04–1.14)
Behavior of the skin in the sun I get tanned easily, I don’t get burn 902(38.98) 1 (reference) 8.89 <0.001 0.88
I rarely get burned and then I get tanned 457(19.75) 1.11 (1.06–1.17)
I get burned and then I get tanned 560(24.20) 1.14 (1.08–1.19)
I get burned and almost never I get tanned 397(17.07) 1.22 (1.15–1.29)
Model adjusted for propensity score
F statistics obtained as Chi square / (number of categories in the phenotype– 1). F, p and R2 refer to the comparison between the model with genetic score + propensity
score and the model with only the propensity score
https://doi.org/10.1371/journal.pone.0201750.t002
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and prostate size[45,46] and meta-analyses have shown an association between prostate[46]
and breast[47] cancer and vitamin D. The usual ways for controlling confounders in observa-
tional studies include multivariate regression, stratified analysis and other; unfortunately, no
method guarantees the absence of residual confounding.
Information bias could also have influenced results from observational studies, since most
studies reporting associations between phototype and cancer have used data reported by the
participants through an interview (although these variables may very well be reported accu-
rately, however, there could be some subjectivity in the answer too) about hair, skin and eyes
color, instead of objectively measured data. A prior study on sun exposure and PCa risk,
described darker pigmentation on the forehead (measured using a reflectometer), was associ-
ated with reduced PCa risk [48]. Conversely, other studies have observed that lower sun expo-
sure was associated with an increased risk of PCa [43,44,49]. A reason for this may be that
people who are sun -sensitive avoid and / or protect themselves with clothing and sun cream
to prevent sunburn and skin cancer.
On the other hand, reverse causality may also partly explain the association between photo-
type and cancer reported in retrospective or cross-sectional studies. We have also identified
two studies that directly examined the relationship between pigmentation phenotypes and the
incidence of PCa, another hormone-dependent tumor and their results were somewhat con-
tradictory: On the one hand, Bonilla et al found that British white men who were more likely
to have freckles, a lighter skin color and were more prone to burning than tanning had a
Fig 1. Relationship in controls, between phototype pigmentation and the genetic pigmentation score of the phototype in quartiles. Relative Risk Ratio (RRR).
https://doi.org/10.1371/journal.pone.0201750.g001
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Table 3. Association between genetic pigmentation scores of phototype and prostate and breast cancer.
Prostate cancer Breast cancer
SCORES Category Cases/Controls OR (95% CI) p Cases/Controls OR (95% CI) p
GPS All 813/1084 1.01 (0.97–1.05) 0.706 1133/1236 0.99 (0.96–1.03) 0.637
< 65 years 341/428 1.05 (0.99–1.12) 0.129 820/766 0.99 (0.95–1.03) 0.621
65 years 472/656 0.97 (0.92–1.03) 0.343 313/470 1.00 (0.94–1.08) 0.909
BMI < 25 Kg/m2 205/256 0.96 (0.88–1.05) 0.392 511/577 0.98 (0.93–1.04) 0.513
BMI25 Kg/m2 596/803 1.03 (0.98–1.07) 0.297 551/537 1.00 (0.94–1.05) 0.865
premenopausal 403/361 0.98 (0.92–1.05) 0.524
postmenopausal 729/875 0.99 (0.95–1.04) 0.825
Hair color score All 816/1092 1.01 (0.96–1.06) 0.753 1138/1240 0.97 (0.93–1.02) 0.265
< 65 years 341/431 1.02 (0.94–1.10) 0.709 825/769 0.96 (0.91–1.02) 0.171
65 years 475/661 1.00 (0.94–1.07) 0.995 313/471 1.00 (0.92–1.09) 0.974
BMI < 25 Kg/m2 206/261 0.96 (0.87–1.07) 0.465 513/579 0.98 (0.92–1.04) 0.481
BMI25 Kg/m2 598/806 1.02 (0.97–1.08) 0.458 554/539 0.97 (0.91–1.04) 0.429
premenopausal 404/362 0.99 (0.92–1.08) 0.890
postmenopausal 733/878 0.96 (0.91–1.02) 0.199
Skin color score All 815/1089 1.00 (0.95–1.05) 0.94 1136/1237 1.00 (0.96–1.05) 0.901
< 65 years 341/430 1.02 (0.95–1.10) 0.621 823/767 1.01 (0.95–1.06) 0.820
65 years 474/659 0.98 (0.92–1.05) 0.558 313/470 1.01 (0.92–1.10) 0.882
BMI < 25 Kg/m2 206/260 0.92 (0.83–1.02) 0.109 513/578 0.99 (0.93–1.06) 0.851
BMI25 Kg/m2 597/804 1.03 (0.98–1.09) 0.262 552/537 1.01 (0.95–1.08) 0.702
premenopausal 404/361 1.02 (0.94–1.10) 0.687
postmenopausal 731/876 0.99 (0.94–1.05) 0.831
Eye color score All 816/1091 1.01 (0.95–1.07) 0.741 1136/1240 1.01 (0.96–1.07) 0.574
< 65 years 341/431 1.05 (0.96–1.15) 0.271 823/769 1.00 (0.94–1.07) 0.924
65 years 475/660 0.98 (0.91–1.05) 0.584 313/471 1.05 (0.95–1.15) 0.344
BMI < 25 Kg/m2 206/260 1.00 (0.89–1.12) 0.993 512/579 1.00 (0.93–1.08) 0.957
BMI25 Kg/m2 598/806 1.02 (0.95–1.08) 0.623 553/539 1.03 (0.95–1.10) 0.488
premenopausal 404/362 1.01 (0.92–1.11) 0.815
postmenopausal 731/878 1.01 (0.95–1.08) 0.658
Freckles score All 814/1087 1.00 (0.93–1.08) 0.983 1135/1239 1.02 (0.96–1.09) 0.514
< 65 years 341/428 0.98 (0.88–1.10) 0.784 822/768 1.04 (0.96–1.12) 0.325
65 years 473/659 1.00 (0.91–1.11) 0.925 313/471 0.99 (0.88–1.12) 0.921
BMI < 25 Kg/m2 205/256 0.94 (0.81–1.10) 0.433 511/578 0.99 (0.91–1.09) 0.91
BMI25 Kg/m2 597/806 1.03 (0.95–1.12) 0.481 553/539 1.05 (0.95–1.15) 0.339
premenopausal 403/362 1.01 (0.91–1.13) 0.799
postmenopausal 731/877 1.03 (0.95–1.11) 0.526
Tanning score All 1108/1484 1.01 (0.97–1.06) 0.596 1736/1906 0.99 (0.95–1.03) 0.684
< 65 years 461/567 1.04 (0.97–1.12) 0.29 1269/1170 0.99 (0.94–1.04) 0.763
65 years 647/917 0.98 (0.92–1.05) 0.604 467/736 1.00 (0.92–1.08) 0.932
BMI < 25 Kg/m2 279/341 0.93 (0.84–1.02) 0.136 772/847 0.98 (0.93–1.05) 0.604
BMI25 Kg/m2 810/1002 1.05 (0.99–1.11) 0.109 834/796 1.00 (0.94–1.06) 0.932
premenopausal 611/547 1.00 (0.93–1.08) 0.954
postmenopausal 1124/1353 0.99 (0.94–1.04) 0.628
Model adjusted for propensity score
https://doi.org/10.1371/journal.pone.0201750.t003
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higher risk of developing PCa than men without such variant[26]; on the other hand, Wein-
stein et al. paper found no association between eye color and skin phototype[27], but red-
haired participants in the study were significantly less likely to develop PCa than men with
light brown hair[27]. However, it is unclear whether these associations are causal; in fact, the
findings may be due to confounders simultaneously associated with the fair skin phototype
and cancer, such as ultraviolet radiation (UV) exposure, seasons of the year, level of vitamin D
or use of sun cream with high protection. As these potential confounders may act in different
directions, one cannot discard that different composition of the studied populations could
have dealt to such a contradictory results.
Mendelian randomization
Mendelian randomization allows the researchers to control for known and unknown con-
founding factors if these factors are not associated with the genetic instruments and to elimi-
nate information bias, overcoming the problems that are frequent in strictly observational
studies. Firstly, genotypes are determined at conception and remain constant throughout life;
they are randomly distributed in conception in relation to potential confounding factors. Sec-
ondly, Mendelian randomization is not influenced by reverse causation, since BC or PCa can-
not change the germline genotype of an individual. If the phototype is truly a causal risk factor
in cancer development, it would be expected that genetic variants associated with the photo-
type will also increase cancer risk.
The GPS we have created was not derived from our data as the SNPs were selected from the
literature. It fulfills all three criteria for Mendelian randomization: Firstly, it is associated with
phototype in controls Secondly, the GPS was not associated with known risk factors for pros-
tate or BC, which would have been confounders in the phototype–cancer relationship; of note,
this way of testing cannot rule out associations with unmeasured confounders. The third Men-
delian randomization assumption–i.e.: the GPS is not associated with cancer conditioned to
phototype and confounders (= no pleiotropy)- cannot be directly tested with data. In this
regard, MR-Egger regression could be considered a sensitivity analysis as it allows for estima-
tion of the bias introduced by a putative direct effect (α in S6 Table) and once such bias was
removed (β in S6 Table), the true phototype–cancer link was apparent. According to MR-Eg-
ger results, the possibility of pleiotropy can be excluded for hair color, eye color and freckles–
cancer relationship, but not for skin color and skin behavior in the sun–PCa relationships. In
this regard, MR-Egger suggested that fair skin and skins getting easily burned or tanned were
associated with lower risk of PCa; the putative effects suggested by MR-Egger regression, how-
ever, seem to be unimportant and require further confirmation.
As far as we know, there is only one article that uses three predictive genetic pigmentation
scores associated with phototypes[27] (6 SNPs used for building a skin color score, 13 for a
tanning score and 8 SNPs for a freckling score). We have created five genetic pigmentation
scores one for each characteristic of the phototype and another global one that agglutinates the
whole phototype, improving the predictive capacity of Bonilla et al.[27]. Bonilla et al also
observed that individuals who had a tendency to burn and spent less time sunbathing, had less
vitamin D level in plasma and a greater susceptibility to PCa. However, in our research, using
a global score with the 17 SNPs published in the literature up to January 2017, we have failed
to find that association with PCa. This negative result was confirmed in a sensitivity analysis of
ours using phototype-specific genetic pigmentation scores.
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Limitations
Our study has some limitations. Firstly, genotyping was available only for 65% of our patients.
Secondly, the sample size for PCa in our study is relatively small when compared with a previ-
ous Mendelian randomization study (1136 cases in Bonilla et al [27] vs. 817cases in our analy-
sis); therefore, our study could have little power to detect small causal effects in BC and PCa if
they exist; also, chance could still play a role in the results. Thirdly, our data proceed from a
case-control study, so self-selection -especially in controls- cannot be ruled out; a putative
mechanism for self-selection could be that people with higher education would be more prone
to participate and would have fairer phototype; however, controls scarcely displayed such asso-
ciation between phototype and education level, with Goodman-Kruskal gamma = 0.02 in men
and 0.03 in women, which makes it difficult to be a source of bias. In fifth place, we have
selected only participants of Caucasian origin; Spain has largely been a country to emigrate
from, although this trend changed around 1995, when Spain begun to receive immigrants
mainly from North Africa, South America and Eastern Europe; most of them were young
adults, which makes them unlikely to be selected for our study. This selection could limit the
generalization of our results.
In conclusion, our results demonstrate that hormone-dependent breast and prostate can-
cers are not associated with eye color, hair color, skin phototype, and the presence of freckles.
It is also shown that genetic pigmentation scores can be used as instrumental variables for pig-
mentation to avoid confounding and problems related to information reliability.
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